8-K: Kintara Therapeutics Announces Third Quarter Fiscal 2024 Results and Merger with TuHURA Biosciences

Kintara Therapeutics reported its third quarter fiscal 2024 financial results, highlighted by a reduced net loss and announced a merger agreement with TuHURA Biosciences.

Summary

• Kintara Therapeutics announced its financial results for the third fiscal quarter ended March 31, 2024, reporting a net loss of approximately $2.0 million, or $0.05 per share.
• This is an improvement compared to the same period last year, which saw a net loss of approximately $3.3 million, or $1.94 per share.
• The reduced loss was primarily due to lower research and development expenses, particularly in clinical development costs.
• General and administrative costs increased due to professional fees related to the proposed merger with TuHURA Biosciences.
• As of March 31, 2024, Kintara had approximately $6.35 million in cash and cash equivalents.
• Kintara also announced a definitive merger agreement with TuHURA Biosciences, where TuHURA will become a wholly-owned subsidiary of Kintara.
• Kintara's existing stockholders will receive contingent value rights (CVR) that could result in additional shares if a minimum of 10 patients complete 8 weeks of follow-up in the REM-001 study by December 31, 2025.
• Post-merger, Kintara's stockholders are expected to own approximately 2.85% of the combined company, or approximately 5.45% if the CVR milestone is achieved.
• The merger is expected to close in the third quarter of 2024.
• Kintara also expanded the inclusion criteria for its REM-001 study in cutaneous metastatic breast cancer to include patients receiving pembrolizumab for at least three months.
• The company initiated an open-label 15-patient study evaluating REM-001, with the majority of costs covered by a $2.0 million SBIR grant from the NIH.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The reduced net loss and merger announcement are positive, but the small ownership stake for existing shareholders and the risks associated with the merger temper the overall sentiment. The company is making progress but faces challenges.

Positives

• Kintara's net loss decreased significantly year-over-year, indicating improved financial performance.
• The company's cash position improved substantially, with approximately $6.35 million in cash and cash equivalents.
• The merger with TuHURA Biosciences could provide strategic advantages and growth opportunities.
• The REM-001 study is progressing with expanded inclusion criteria and funding from an NIH grant.
• Kintara regained compliance with Nasdaq's minimum stockholders' equity requirement.

Negatives

• General and administrative costs increased due to professional fees related to the proposed merger.
• Kintara's stockholders will own a relatively small percentage of the combined company post-merger, approximately 2.85% or 5.45% if the CVR milestone is achieved.
• The merger is subject to various conditions, including stockholder approval, which introduces uncertainty.

Risks

• The merger with TuHURA is subject to various risks, including failure to obtain stockholder approval and uncertainties regarding the timing of the closing.
• There are risks related to estimating operating expenses and the impact of any delays on the combined company's cash resources.
• The merger could lead to unexpected costs, charges, or expenses.
• There is a risk that the combined business of TuHURA and Kintara may not be successful.
• The company faces risks related to protecting intellectual property rights and competitive responses to the merger.
• The company is subject to legislative, regulatory, political and economic developments.

Future Outlook

The company anticipates the merger with TuHURA to close in the third quarter of 2024 and is focused on advancing its clinical programs, including the REM-001 study and TuHURA's IFx-2.0 product candidate.

Management Comments

• Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.
• Kintara is developing therapeutics for clear unmet medical needs with reduced risk development programs.

Industry Context

The merger with TuHURA reflects a trend in the biotech industry towards consolidation and strategic partnerships to enhance drug development pipelines and address unmet medical needs in oncology. The focus on immuno-oncology and personalized cancer vaccines aligns with current industry trends.

Comparison to Industry Standards

• Kintara's Q3 2024 net loss of $2.0 million is an improvement compared to its Q3 2023 loss of $3.3 million, indicating progress in cost management.
• However, the company's cash position of $6.35 million is relatively low compared to other publicly traded biotech companies, which often have tens or hundreds of millions in cash reserves.
• The merger with TuHURA is a strategic move to combine resources and expertise, similar to other mergers in the biotech sector, such as the recent merger between Jazz Pharmaceuticals and GW Pharmaceuticals.
• The REM-001 study is focused on a specific niche of cutaneous metastatic breast cancer, which is a smaller market compared to broader oncology indications targeted by companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo).
• TuHURA's IFx-2.0 vaccine is in Phase 3, which is a late-stage development, similar to other companies like Moderna and BioNTech that have advanced mRNA vaccines to market.

Stakeholder Impact

• Shareholders of Kintara will receive contingent value rights (CVR) and a small ownership stake in the combined company.
• Employees of both Kintara and TuHURA may experience changes due to the merger.
• Customers and patients may benefit from the combined company's expanded pipeline and resources.
• Creditors and suppliers may be impacted by the merger, but the details are not specified.

Next Steps

• Kintara will seek stockholder approval for the merger with TuHURA.
• The company will work towards closing the merger in the third quarter of 2024.
• Kintara will continue to advance the REM-001 study and TuHURA's IFx-2.0 product candidate.
• The company will prepare a definitive proxy statement/prospectus for the merger.

Key Dates

Keywords

Merger, Kintara Therapeutics, TuHURA Biosciences, REM-001, Cutaneous Metastatic Breast Cancer, Financial Results, Clinical Trial, Immunotherapy, Contingent Value Rights, SBIR Grant